| [1] |
Son H, Khan SM, Rahaman J, et al. Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics, 2011, 31(2):569-583. doi: 10.1148/rg.312105713
|
| [2] |
Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma:the Gynecologic Oncology Group experience. J Clin Oncol, 1991, 9(7):1138-1150. doi: 10.1200/JCO.1991.9.7.1138
|
| [3] |
吴湖炳, 王全师, 王明芳, 等. PET/CT显像在探查卵巢癌术后复发、转移中的应用.中华核医学杂志, 2006, 26(4):197-200. doi: 10.3760/cma.j.issn.2095-2848.2006.04.001
|
| [4] |
Havrilesky LJ, Kulasingam SL, Matchar DB, et al. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol, 2005, 97(1):183-191.
|
| [5] |
Sironi S, Messa C, Mangili G, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer:correlation with histologic findings. Radiology, 2004, 233(2):433-440.
|
| [6] |
赵军, 管一晖, 左传涛, 等. 18F-FDG PET/CT在探测卵巢癌术后复发和转移中的价值.中国肿瘤, 2007, 16(3):187-189. doi: 10.3969/j.issn.1004-0242.2007.03.012
|
| [7] |
Rubini G, Altini C, Notaristefano A, et al. Peritoneal carcinomatosis from ovarian cancer:role of 18F-FDG-PET/CT and CA125. Recenti Prog Med, 2012, 103(11):510-514.
|
| [8] |
Palomar A, Nanni C, Castellucci P, et al. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. Mol Imaging Biol, 2012, 14(1):123-129.
|